Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | PRKDC | P78527 | 3/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30845658 | 1.00 | GPR119 (0.38) | GPR119PIK3CAPRKDCMTORSUV39H2 | |
| SCHEMBL30845712 | 1.00 | GPR119 (0.38) | GPR119PIK3CAPRKDCMTORSUV39H2 | |
| SCHEMBL21773285 | 0.91 | MMP9 (0.36) | ALDH1A1 | |
| SCHEMBL21773278 | 0.91 | MMP9 (0.36) | ALDH1A1 | |
| SCHEMBL21773280 | 0.91 | MMP9 (0.36) | ALDH1A1 | |
| SCHEMBL28556812 | 0.88 | ALDH1A1 (0.42) | GPR119PIK3CAPRKDCMTORALDH1A1 | |
| SCHEMBL30845610 | 0.88 | ALDH1A1 (0.42) | GPR119PIK3CAPRKDCMTORALDH1A1 | |
| SCHEMBL21789465 | 0.88 | ALDH1A1 (0.42) | GPR119PIK3CAPRKDCMTORALDH1A1 | |
| SCHEMBL21789154 | 0.87 | SCN8A (0.40) | GPR119CETPSLC2A1ACLY | |
| SCHEMBL30845699 | 0.87 | SCN8A (0.40) | GPR119CETPSLC2A1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| WO-2020047312-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | GPR119 1639/4885PIK3CA 1976/4885PRKDC 4109/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | GPR119 1639/4885PIK3CA 1976/4885PRKDC 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.